GF FUND MANAGEMENT CO. LTD.
Position in PTGX — Protagonist Therapeutics, Inc
CIK 2057060
GUANGZHOU, F4
Position in PTGX
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$165,850
+$17,869 QoQ
Shares Held
1,353
-3.6% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#267
of 341 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GF FUND MANAGEMENT CO. LTD. holds $72,227,940 across 200 Biotechnology names. PTGX ranks #33 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
62,678 | $31,134,042 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
25,824 | $16,102,296 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
29,770 | $8,961,663 | |
| 4 | INCY |
Incyte Corp
|
8,590 | $973,762 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
4,195 | $785,639 | |
| 6 | MRNA |
Moderna, Inc.
|
7,839 | $548,965 | |
| 7 | RPRX |
Royalty Pharma plc
|
9,065 | $508,274 | |
| 8 | ARGX |
Argenx SE
|
546 | $506,562 |
All Filings in PTGX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $165,850 | 1,353 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $147,981 | 1,404 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $107,166 | 1,227 | Shares | Sole | 2026-01-27 | |
| 2025-09-30 | $88,883 | 1,338 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $84,342 | 1,526 | Shares | Sole | 2025-07-22 | |
| 2025-03-31 | $73,797 | 1,526 | Shares | Sole | 2025-04-29 | |
| 2024-12-31 | $48,288 | 1,251 | Shares | Sole | 2025-02-19 | |
| No filing history on record for this holder in this stock. | ||||||